Loading...
Market
Status of HI-Bio integration into Biogen by end of 2025
4
Resolution / Starting Odds
Fully integrated by mid-2025 • 25%
Fully integrated by end of 2025 • 25%
Integration delayed beyond 2025 • 25%
Integration halted or reversed • 25%
Biogen press releases or official statements
Story
Biogen (Nasdaq: $BIIB) to Acquire HI-Bio for $1.15 Billion Upfront and $650 Million in Milestones
May 22, 2024, 11:39 AM
Biogen Inc. (Nasdaq: $BIIB) announced on Wednesday that it has agreed to acquire privately held Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in potential milestone payments. The acquisition aims to bolster Biogen's late-stage pipeline and expand its immunology portfolio. HI-Bio is a clinical-stage biotechnology company focused on targeted therapies, including Felzartamab, a Phase 3 CD38 antibody for immunosuppression and other immune-related diseases.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increase by more than 5% • 25%
Increase by less than 5% • 25%
Decrease by less than 5% • 25%
Decrease by more than 5% • 25%
Fully Integrated • 33%
Partially Integrated • 33%
Integration Delayed • 33%
Biosimilars launched • 50%
Biosimilars not launched • 50%
Full integration • 33%
Partial integration • 33%
Operates independently • 34%
Full $1.7 billion paid • 33%
Partial milestone payments made • 33%
No milestone payments made • 34%
Fully integrated • 33%
Partially integrated • 33%
Integration delayed or problematic • 34%
No milestones achieved • 33%
Only first milestone achieved • 33%
All milestones achieved • 33%